Biotech

All Articles

Analysts examine Avidity's DMD win, uncovering nuances in data

.Avidity Biosciences amazed financiers along with phase 1/2 data in Duchenne muscular dystrophy (DMD...

Actinogen's cortisol blocker neglects period 2 depression research study

.Actinogen Medical's cortisol blocker has skipped the major endpoint of a period 2 research in depre...

Bivictrix decides going private only method to take ADC into medical clinic

.Antibody-drug conjugates (ADCs) have actually been at the facility of lots of a billion-dollar biob...

TPG bests up funds to $580M for expenditures across lifestyle sciences

.Property manager TPG, which has supported biotechs like Sionna Therapeutics and also Santa Clam Ana...

Merck ceases period 3 TIGIT test in bronchi cancer cells for futility

.Merck &amp Co.'s TIGIT course has endured another drawback. Months after shuttering a stage 3 cance...

After a difficult year, Exscientia folds into Recursion

.After a year described by pipeline cuts, the departure of its chief executive officer as well as un...

Cullinan, after $25M package, return bispecific to Harbour

.Cullinan Therapy was wowed good enough with Harbour BioMed's bispecific immune system activator tha...

A nearer check out Brutal Biotech's Intense 15

.In this particular week's episode of "The Leading Pipe," our team are actually diving into Strong B...

Lilly encounters phase 2 breakdown of tau-targeting med

.The confetti is actually still flying coming from Eli Lilly's gathering celebrating the approval of...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Invite to recently's Chutes &amp Ladders, our summary of considerable management hirings, shootings...